Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on May 13, 2005. The filing discloses the entry into a material definitive agreement regarding executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate governance transaction rather than financial performance.
Material Changes
The material change reported is the grant of a nonstatutory stock option to Phillip A. Sharp, Ph.D., a member of the Board of Directors. The key terms of this agreement are:
- Shares Granted: 100,000 shares of common stock.
- Exercise Price: $7.77 per share.
- Plan: 2004 Stock Incentive Plan.
- Vesting Schedule: 25% vests on the first anniversary of the grant date; an additional 6.25% vests at the end of each successive three-month period thereafter until the fourth anniversary.
- Condition: Vesting is contingent upon Dr. Sharp continuing to serve as a Board member.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on financial performance, or specific risk factors beyond the standard contingencies of the stock option vesting schedule.
Investor Verification Checklist
- Verify the current market price of Alnylam common stock relative to the $7.77 exercise price.
- Confirm Dr. Sharp's continued service on the Board of Directors to ensure vesting conditions are met.
- Review the total outstanding shares and dilution impact of the 100,000 new options.
- Check the remaining share availability under the 2004 Stock Incentive Plan.